{"data":[{"accessionNo":"0000093751-26-000484","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS INC","ticker":"NTLA","cusip":"45826J105","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":9234987,"percentOfClass":6.8,"filedAt":"2026-08-07"},{"accessionNo":"0002100119-26-000581","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics Inc","ticker":"NTLA","cusip":"45826J105","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Capital Management","reportingCik":null,"personType":"IA","sharesOwned":5945571,"percentOfClass":5.03,"filedAt":"2026-04-30"},{"accessionNo":"0002100121-26-000395","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics Inc","ticker":"NTLA","cusip":"45826J105","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Portfolio Management","reportingCik":null,"personType":"IA","sharesOwned":6266007,"percentOfClass":5.3,"filedAt":"2026-04-29"},{"accessionNo":"0000102909-26-001517","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics Inc","ticker":"NTLA","cusip":"45826J105","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27"},{"accessionNo":"0000886982-26-000085","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"THE GOLDMAN SACHS GROUP, INC.","reportingCik":null,"personType":"HC,CO","sharesOwned":3157178.33,"percentOfClass":2.7,"filedAt":"2026-02-12"},{"accessionNo":"0000886982-26-000085","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"GOLDMAN SACHS & CO. LLC","reportingCik":null,"personType":"BD,OO,IA","sharesOwned":3157178.33,"percentOfClass":2.7,"filedAt":"2026-02-12"},{"accessionNo":"0001999371-26-003032","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC","ticker":"NTLA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Contrarius Investment Management Ltd","reportingCik":null,"personType":"FI","sharesOwned":714480,"percentOfClass":0.6,"filedAt":"2026-02-11"},{"accessionNo":"0001999371-26-003032","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC","ticker":"NTLA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Contrarius Investment Management (Bermuda) Ltd","reportingCik":null,"personType":"FI","sharesOwned":714480,"percentOfClass":0.6,"filedAt":"2026-02-11"},{"accessionNo":"0000093751-26-000056","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS INC","ticker":"NTLA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":6418836,"percentOfClass":5.5,"filedAt":"2026-02-09"},{"accessionNo":"0001104659-26-009584","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics, Inc.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"ARK Investment Management LLC","reportingCik":null,"personType":"IA","sharesOwned":14207324,"percentOfClass":12.27,"filedAt":"2026-02-03"},{"accessionNo":"0001104659-26-009584","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics, Inc.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Catherine D. Wood","reportingCik":null,"personType":"HC,IN","sharesOwned":14207324,"percentOfClass":12.27,"filedAt":"2026-02-03"},{"accessionNo":"0000102909-26-000156","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics Inc","ticker":"NTLA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":13010001,"percentOfClass":11.23,"filedAt":"2026-01-30"},{"accessionNo":"0001999371-25-017496","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC","ticker":"NTLA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"Contrarius Investment Management Ltd","reportingCik":null,"personType":"FI","sharesOwned":5889936,"percentOfClass":5.5,"filedAt":"2025-11-12"},{"accessionNo":"0001999371-25-017496","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC","ticker":"NTLA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"Contrarius Investment Management (Bermuda) Ltd","reportingCik":null,"personType":"FI","sharesOwned":5889936,"percentOfClass":5.5,"filedAt":"2025-11-12"},{"accessionNo":"0000886982-25-001471","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"THE GOLDMAN SACHS GROUP, INC.","reportingCik":null,"personType":"HC,CO","sharesOwned":5498262.38,"percentOfClass":5.1,"filedAt":"2025-11-12"},{"accessionNo":"0000886982-25-001471","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001652130","issuerName":"INTELLIA THERAPEUTICS, INC.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"GOLDMAN SACHS & CO. LLC","reportingCik":null,"personType":"BD,OO,IA","sharesOwned":5498262.38,"percentOfClass":5.1,"filedAt":"2025-11-12"},{"accessionNo":"0001104659-25-106358","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics, Inc.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"ARK Investment Management LLC","reportingCik":null,"personType":"IA","sharesOwned":11919178,"percentOfClass":11.1,"filedAt":"2025-11-04"},{"accessionNo":"0001104659-25-106358","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001652130","issuerName":"Intellia Therapeutics, Inc.","ticker":"NTLA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Catherine D. Wood","reportingCik":null,"personType":"HC,IN","sharesOwned":11919178,"percentOfClass":11.1,"filedAt":"2025-11-04"}],"updatedAt":"2026-10-15T14:05:33.118Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}